Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | RARB | P10826 | 3/20 | 0.57 |
| ▸ | PLK1 | P53350 | 1/20 | 0.57 |
| ▸ | THRA | P10827 | 1/20 | 0.56 |
| ▸ | THRB | P10828 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dimethylamine SCHEMBL7749463 | 0.95 | PLK1 (0.61) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL570964 | 0.95 | RARB (0.58) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL6899814 | 0.93 | THRA (0.59) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL11393726 | 0.93 | THRA (0.59) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL12040863 | 0.93 | THRA (0.59) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL6900234 | 0.93 | THRA (0.59) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL3796237 | 0.93 | THRA (0.59) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL6123675 | 0.93 | THRA (0.59) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL21656942 | 0.92 | ESR1 (0.51) | ESR1CA12CA1CA2CA7 | |
| SCHEMBL18821726 | 0.91 | MAPT (0.58) | ESR1CA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118909169-A | Solid catalyst component for olefin polymerization reaction, preparation method and application thereof | 中国石油化工股份有限公司 | 2024-11-08 | — | — | CN | claimed |
| CN-118909170-A | Catalyst system for preparing olefin polymer and application thereof | 中国石油化工股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118909168-A | Catalyst system for preparing olefin polymer and application thereof | 中国石油化工股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| CN-118909169-A | Solid catalyst component for olefin polymerization reaction, preparation method and application thereof | 中国石油化工股份有限公司 | 2024-11-08 | — | — | CN | disclosed |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2023-05-18 | — | — | US | disclosed |
| EP-4124616-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | Alkermes Pharma Ireland Limited (IE) | 2023-02-01 | — | — | EP | disclosed |
| EP-2445502-B2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES PHARMA IRELAND LTD (IE) | 2022-09-28 | — | — | EP | disclosed |
| EP-2445343-B1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES PHARMA IRELAND LTD (IE) | 2021-08-04 | — | — | EP | disclosed |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-11-03 | — | — | US | disclosed |
| US-10428058-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-10-01 | — | — | US | disclosed |
| EP-0760359-B1 | Method for preparing aromatic carbonate | MITSUBISHI GAS CHEMICAL CO (JP) | 1999-10-20 | — | — | EP | disclosed |
| US-5714627-A | REACTING A DIALKYL CARBONATE WITH AN AROMATIC CARBOXYLIC ACID ARYL ESTER IN THE PRESENCE OF A CATALYST | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1998-02-03 | — | — | US | disclosed |
| EP-0760359-A1 | Method for preparing aromatic carbonate | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 1997-03-05 | — | — | EP | disclosed |
| US-4562280-A | WITH CHLOROMETHYL ALKYL ETHER IN PRESENCE OF CATALYIC FERRIC OR STANNIC CHLORIDE | THE DOW CHEMICAL COMPANY (US) | 1985-12-31 | — | — | US | disclosed |
| US-4507450-A | COORDINATION CATALYSTS | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1985-03-26 | — | — | US | disclosed |
| US-4336360-A | IN THE PRESENCE OF A CATALYST COMPLEX | MONTECATINI EDISON S.P.A. (IT) | 1982-06-22 | — | — | US | disclosed |
| US-4229558-A | HAVING HIGH ISOTACTIC INDEX BY USING A CATALYST PREPARED FROM A MAGNESIUM GRIGNARD REAGENT, TITANIUM HALIDE AN ETHER AND A CARBOXYLIC ESTER COMBINED WITH AN ORGANOALUMINUM COMPOUND | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1980-10-21 | — | — | US | disclosed |
| US-4187196-A | REACTING HALOGENATED TITANIUM COMPOUND WITH MAGNESIUM OR MANGANESE DIHALIDE | MONTEDISON S.P.A. (IT) | 1980-02-05 | — | — | US | disclosed |
| US-4156063-A | USING A CATALYST CONTAINING THE REACTION PRODUCT OF AN ALUMINUM COMPOUND AND AN ESTER WITH A SUPPORT CONTAINING THE REACTION PRODUCT OF A TITANIUM COMPOUND AND A MAGNESIUM OR MANGANESE BIHALIDE | Montecanti Edison, S.p.A. (IT) | 1979-05-22 | — | — | US | disclosed |
| US-4107414-A | Process for the stereoregular polymerization of alpha olefins | MONTECATINI EDISON S.P.A. (IT) | 1978-08-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428058-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | ESR1 2443/4885CA12 271/4885CA1 377/4885 |
| US-20230150941-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | ESR1 2319/4885CA12 3134/4885CA1 2576/4885 |
| US-10822306-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | ESR1 2319/4885CA12 3134/4885CA1 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.